COVID-19 Update

2020-04-10T09:46:32+01:00April 10th, 2020|Uncategorised|

The current situation regarding the Coronavirus disease (COVID-19) is significantly impacting the research community, including the PD-MitoQUANT international consortium. We anticipate that the precise nature of these impacts will evolve over the coming weeks and months. Our institutions' priority is the safety and wellbeing of all people, including our own research teams. The consortium is working together to come up with solutions to reduce delays to the project as a result of the practical measures taken to contain the virus.

PD-MitoQUANT Partner Spotlight – H. Lundbeck A/S

2020-04-10T10:39:26+01:00April 8th, 2020|News, Partner in the Spotlight|

With headquarters in Denmark, Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with brain diseases. For this purpose, Lundbeck is engaged in research, drug discovery development, manufacturing, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at disease areas within psychiatry and neurology. Within PD-MitoQUANT, Lundbeck: is scientific co-leader as part of the PD-MitoQUANT Executive Team, evaluates a range of α-synuclein (α-αSyn) fibril species to select the most [...]

PROJECT FACTS

 

  • Grant agreement number 821522
  • IMI2 JU contribution €4,617,933.75
  • Duration 36 months
  • Starting date 1 February 2019

 

FUNDING ACKNOWLEDGEMENT

 

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 821522. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Parkinson’s UK.

The material presented and views expressed here reflect the author’s view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.

 

Go to Top